BRPI0515645A - métodos terapêuticos, composições, compostos e usos de compostos - Google Patents

métodos terapêuticos, composições, compostos e usos de compostos

Info

Publication number
BRPI0515645A
BRPI0515645A BRPI0515645-9A BRPI0515645A BRPI0515645A BR PI0515645 A BRPI0515645 A BR PI0515645A BR PI0515645 A BRPI0515645 A BR PI0515645A BR PI0515645 A BRPI0515645 A BR PI0515645A
Authority
BR
Brazil
Prior art keywords
compounds
compositions
therapeutic methods
ghb
analog
Prior art date
Application number
BRPI0515645-9A
Other languages
English (en)
Inventor
Mortimer Mamelak
Original Assignee
Orphan Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orphan Medical Inc filed Critical Orphan Medical Inc
Publication of BRPI0515645A publication Critical patent/BRPI0515645A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MéTODOS TERAPêUTICOS, COMPOSIçõES, COMPOSTOS E USOS DE COMPOSTOS A invenção apresenta uma combinação de gama-hidróxi butirato de sódio (GHB) ou de um pró-medicamento ou um análogo do mesmo, com um composto que inibe o metabolismo do GHB ou do análogo de GHB in vivo, desse modo prolongando ou intensificando a sua bioatividade.
BRPI0515645-9A 2004-09-07 2005-09-07 métodos terapêuticos, composições, compostos e usos de compostos BRPI0515645A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60765104P 2004-09-07 2004-09-07
PCT/US2005/031717 WO2006029155A2 (en) 2004-09-07 2005-09-07 Improved ghb compositions

Publications (1)

Publication Number Publication Date
BRPI0515645A true BRPI0515645A (pt) 2008-03-04

Family

ID=36036948

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515645-9A BRPI0515645A (pt) 2004-09-07 2005-09-07 métodos terapêuticos, composições, compostos e usos de compostos

Country Status (9)

Country Link
US (1) US20060069040A1 (pt)
EP (1) EP1786437A4 (pt)
JP (1) JP2008512386A (pt)
KR (1) KR20070100686A (pt)
AU (1) AU2005282468B2 (pt)
BR (1) BRPI0515645A (pt)
CA (1) CA2579576A1 (pt)
MX (1) MX2007002682A (pt)
WO (1) WO2006029155A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
JP5968300B2 (ja) 2010-03-24 2016-08-10 ジャズ、ファーマシューティカルズ、インコーポレイテッドＪａｚｚ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 高用量、水溶性及び吸湿性薬剤基質用の制御放出性剤形
KR20130043198A (ko) * 2010-07-16 2013-04-29 피라말 엔터프라이지즈 리미티드 키나제 억제제로서 치환된 이미다조퀴놀린 유도체
EP2947143B1 (en) * 2013-01-21 2018-07-11 Sekisui Chemical Co., Ltd. Recombinant cell, and method for producing 1,4-butanediol
PT2968208T (pt) 2013-03-13 2022-10-28 Aerial Biopharma Llc Tratamento da cataplexia
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
EP3353145B1 (en) 2015-09-23 2022-09-28 XWPharma Ltd. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
JP7517993B2 (ja) * 2018-10-16 2024-07-17 日本ケミファ株式会社 睡眠の質の改善剤
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0235408B1 (en) * 1984-08-06 1991-01-09 The University Of Toronto Innovations Foundation Pharmaceutical composition and treatment
FR2618331B1 (fr) * 1987-07-23 1991-10-04 Synthelabo Compositions pharmaceutiques utiles pour le traitement de l'uremie
FR2754177B1 (fr) * 1996-10-07 1999-08-06 Sanofi Sa Microspheres pharmaceutiques d'acide valproique pour administration orale
US5990162A (en) * 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
CA2355293C (en) * 1998-12-23 2005-08-16 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
EP1325014B1 (en) * 2000-09-22 2012-05-23 JPI Commercial, LLC Gamma-hydroxybutyrate compositions containing carbohydrate carriers

Also Published As

Publication number Publication date
EP1786437A2 (en) 2007-05-23
MX2007002682A (es) 2008-03-05
KR20070100686A (ko) 2007-10-11
WO2006029155A2 (en) 2006-03-16
WO2006029155A3 (en) 2007-06-28
AU2005282468A1 (en) 2006-03-16
EP1786437A4 (en) 2010-12-08
AU2005282468B2 (en) 2011-04-21
JP2008512386A (ja) 2008-04-24
US20060069040A1 (en) 2006-03-30
CA2579576A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
BRPI0515645A (pt) métodos terapêuticos, composições, compostos e usos de compostos
BRPI0515316A (pt) compostos de imidazoquinolina
ECSP045429A (es) Combinacion de compuestos organicos
DOP2006000269A (es) Derivados de 4-amino-pirrolotriazina sustituida útiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis
BR0212689A (pt) Composição fungicida, método de controle e produto
CR20150097A (es) Composición inmunogénica
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
BR0009564A (pt) Utilização de inibidores da cyp2d6 em terapias de combinação
CY1112387T1 (el) Θεραπευτικη συνθεση περιεχουσα τουλαχιστον ενα παραγωγο της πυρρολοβενζοδιαζεπινης και φλουδαραβινη
BRPI0410503B8 (pt) composição tópica e uso da composição
ECSP056173A (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
ECSP088503A (es) COMPUESTOS de LACTAMa y MÉTODOS DE USO DE LOS MISMOS
BRPI0510627A (pt) combinações que compreendem um agonista do receptor s1p e um inibidor da jak3 quinase
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
AR024516A1 (es) Compuestos bi-aromaticos analogos de la vitamina d, su utilizacion, composicion farmaceutica y composicion cosmetica que comprenden al menos uno de dichos compuestos y utilizacion de dicha composicion cosmetica.
BRPI0519242A2 (pt) uso derivados de 1-aminociclohexano para o tratamento de esclerose méltipla, instabilidade emocional e paralisia pseudobulbar
BR0203902A (pt) Composições de compostos bioquìmicos envolvidos no metabolismo bioenergético das células e método de uso da mesma
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
WO2007075923A3 (en) Treatment of synucleinopathies
AR042051A1 (es) Tratamiento combinado contra el cancer con un compuesto anti-cancerigeno activado por glutationa s- transferasa (gst) y otro tratamiento contra el cancer
GT200600379A (es) Composición farmacéutica sólida que comprende 1-(4-cloro-anilino)-4-(4-piridil-metil)-ftalazina y un modificador del ph
BRPI0620229A8 (pt) formulação
BR0210139A (pt) Composições farmacêuticas
BRPI0212298B8 (pt) composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired